dry eye disease

Lifitegrast (SAR 1118) 是一种整合素淋巴细胞功能相关抗原 1 拮抗剂， 抑制 Jurkat T 细胞附着于ICAM-1的IC50为 2.98 nM。

Diquafosol tetrasodium (INS365) 是一种 P2Y2 受体激动剂，可刺激眼组织粘蛋白的分泌。它可改善泪膜稳定性和视觉功能，作为干眼症的局部治疗。

R-932348 choline, a dual JAK SYK inhibitor, is used potentially for treatment of dry eye disease.

TOP1362 is a Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. TOP1362 strongly inhibited the kinase targets p38α, Syk, Src, and Lck, blocked the rise in p38α expression in hyperosmolar Chang cells, and potently reduced inflammatory cytokine release in cellular models of innate and adaptive immunities. In the EIU model, TOP1362 dose-dependently attenuated the LPS-induced rise in inflammatory cell infiltration and ocular cytokine levels with efficacy comparable to that of dexamethasone.

JAK-IN-30（化合物31）是一种具有水溶性的JAK抑制剂，对JAK2、JAK1、JAK3及TYK2的IC50值分别为2、15、18及2 nM。该化合物作为研究干眼症（DED）的潜在药物而备受关注。

Vezocolmitide 是 ST-100 的组成部分，这种胶原蛋白模拟肽可用于干眼症 (DED) 的研究。